Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, safety, and immunogenicity of simoctocog alfa in previously treated patients with severe haemophilia A
2009-011055-43Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of simoctocog alfa in hemophilia A, sponsored by Octapharma. Primary endpoints: Prophylactic efficacy of simoctocog alfa, Efficacy in treatment of bleeding episodes and 1 more. Started Jun 2009; status: completed.
02
Drugs
simoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2009-011055-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011055-43.